PROCEPT BioRobotics Corpo... (PRCT)
| Bid | 59.27 |
| Market Cap | 3.29B |
| Revenue (ttm) | 236.36M |
| Net Income (ttm) | -96.24M |
| EPS (ttm) | -1.75 |
| PE Ratio (ttm) | -34.26 |
| Forward PE | -57.05 |
| Analyst | Buy |
| Ask | 74.75 |
| Volume | 698,200 |
| Avg. Volume (20D) | 917,723 |
| Open | 61.39 |
| Previous Close | 61.76 |
| Day's Range | 58.11 - 61.55 |
| 52-Week Range | 45.56 - 103.81 |
| Beta | 1.05 |
About PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2...
Analyst Forecast
According to 7 analyst ratings, the average rating for PRCT stock is "Buy." The 12-month stock price forecast is $95, which is an increase of 58.44% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Procept BioRobotics: Strong Growth, But Profitability Seems Far AwayPROCEPT BioRobotics shows strong revenue growth and expanding market presence but struggles with profitability and rising operational costs. The company's HYDROS robotic system and consumables busines...
